Panic disorder has a well-established serotonin component — but the issue is not simply "low serotonin." The problem is that the brain's alarm system fires too easily, and that threshold is partly maintained by how sensitive serotonin receptors are to their signal. When receptor sensitivity is reduced, the alarm system becomes hair-trigger.

Myo-Inositol works as a precursor in the phosphatidylinositol second-messenger system, which directly regulates serotonin receptor sensitivity. This is the mechanism that SSRIs don't fully address — they increase serotonin availability, but not receptor responsiveness. This is why many people on SSRIs still experience panic attacks.

A double-blind crossover trial published in the American Journal of Psychiatry found that Myo-Inositol significantly reduced panic attack frequency compared to placebo. It outperformed fluvoxamine (a standard SSRI) on the same measure with fewer side effects.

Panic disorder is not just a serotonin problem — it is also a cortisol and HPA axis problem. The HPA (hypothalamic-pituitary-adrenal) axis controls the body's stress response. In people prone to panic, this axis is chronically activated, keeping baseline cortisol elevated and the nervous system primed for alarm.

When cortisol is persistently high, the brain's threat-detection sensitivity increases. The amygdala — which triggers the panic response — becomes easier to activate. This is why life stress reliably worsens panic attack frequency: it's not psychological, it's a measurable physiological change in alarm threshold.

KSM-66® is the only ashwagandha extract standardised to a full-spectrum root concentration of 5% withanolides. Multiple randomised controlled trials have demonstrated significant reductions in serum cortisol, perceived stress, and anxiety scores. It is the most researched adaptogen for HPA axis normalisation available in supplement form.

Panic attacks are preceded by a state of hyperarousal — the nervous system running at a heightened baseline, ready to alarm. L-Theanine works to lower that baseline through two mechanisms simultaneously: it increases GABA levels (the brain's primary inhibitory neurotransmitter) and promotes alpha brain wave activity, which is the neural state associated with wakeful calm.

Unlike benzodiazepines, which also enhance GABA but cause sedation and dependence, L-Theanine's effect is anxiolytic without being sedating. It has been shown to reduce subjective anxiety, lower heart rate in stress conditions, and specifically reduce anticipatory anxiety — the state of "waiting for the next one" that is often more disabling than the panic attack itself.

At 400mg, this is a high-end therapeutic dose. Most clinical studies showing benefit use 200–400mg. This dose is specifically chosen to support the nervous system inhibitory effect that panic disorder patients require.

Magnesium is a cofactor in over 300 enzymatic reactions, including the regulation of NMDA glutamate receptors, GABA synthesis, and neuronal excitability. It acts as a natural "brake" on the nervous system — and when magnesium levels are low, that brake fails.

The stress-cortisol cycle accelerates magnesium depletion through the kidneys. This creates a vicious loop: stress triggers cortisol, cortisol depletes magnesium, low magnesium increases neurological sensitivity, which lowers the threshold for both anxiety and panic. Studies have found significantly lower serum magnesium in people with panic disorder compared to controls.

Magnesium glycinate is the most bioavailable oral form — the glycinate chelate increases intestinal absorption and reduces the gastrointestinal side effects common with oxide or citrate forms. At 300mg, this dose is within the range used in clinical supplementation studies showing anxiolytic benefit.

Affron® is a patented saffron extract standardised to a minimum 3.5% Lepticrosalide® — the bioactive compound responsible for saffron's documented effects on mood and anxiety. Generic saffron powders are not standardised and cannot guarantee active compound concentration.

Saffron's anxiolytic mechanism involves inhibition of serotonin reuptake (similar to but milder than SSRIs) and modulation of dopaminergic activity, contributing to emotional regulation. It also has direct anti-inflammatory effects in the central nervous system, which is relevant because neuroinflammation is an emerging factor in anxiety and panic disorder severity.

Multiple double-blind trials using Affron® specifically have shown significant reductions in anxiety scores, with onset within 4 weeks. At 28mg, this is the exact dose used in the majority of positive clinical trials.

5-Hydroxytryptophan (5-HTP) is the immediate precursor to serotonin in the brain. Unlike tryptophan, which must compete with other amino acids to cross the blood-brain barrier, 5-HTP crosses freely and is rapidly converted into serotonin — making it one of the most direct ways to support serotonin synthesis.

In the context of panic disorder, 5-HTP is particularly relevant because panic attacks can be experimentally induced by compounds that challenge the serotonin system, demonstrating a direct link between serotonin signalling and the alarm threshold. Supporting serotonin availability through 5-HTP provides substrate for the receptor system that Myo-Inositol is simultaneously making more sensitive — a complementary mechanism.

Clinical studies have found 5-HTP supplementation reduces anxiety symptoms and has a calming effect on the nervous system, without the side-effect profile of pharmaceutical serotonin manipulation. Sourced here from Griffonia Simplicifolia, which provides the highest natural 5-HTP concentration of any plant source.

Passionflower (Passiflora incarnata) contains flavonoids, including chrysin and vitexin, that interact with GABA-A receptors — the same receptor target as benzodiazepines, but through a different binding site and with a fundamentally different safety and dependency profile. Rather than forcing receptor activation, passionflower's compounds modulate receptor responsiveness, supporting GABA signalling without causing sedation or tolerance.

In a double-blind trial comparing passionflower to oxazepam (a benzodiazepine) for generalised anxiety disorder, passionflower produced equivalent anxiety reduction with significantly fewer impairments to job performance and cognitive function. This makes it particularly relevant for people whose panic disorder affects their ability to function at work.

Passionflower also has some mild MAOI activity, which may contribute to supporting serotonin levels — making it synergistic with both the GABA-focused and serotonin-focused ingredients in this formula.

Lemon Balm (Melissa officinalis) contains rosmarinic acid, which inhibits GABA transaminase — the enzyme that breaks down GABA in the brain. By slowing GABA degradation, Lemon Balm effectively increases GABAergic tone without directly activating GABA receptors, making it a different and complementary mechanism to Passionflower and L-Theanine.

This distinction matters because the combination of ingredients that work through different GABAergic mechanisms is more effective than increasing the dose of a single compound. The formula's GABA support comes from multiple angles: L-Theanine increases GABA production, Passionflower modulates GABA receptors, and Lemon Balm slows GABA breakdown — a layered approach to the same inhibitory pathway.

Clinical studies with Lemon Balm extract have shown significant reductions in anxiety and insomnia at doses of 300mg/day. The 100mg in this formula works synergistically with the other GABAergic ingredients rather than as a standalone dose.

Vitamin B6, as pyridoxal-5-phosphate (its active form), is an essential cofactor at the critical enzymatic step that converts 5-HTP into serotonin, and also the step that converts glutamate into GABA. If B6 is deficient, both of these conversions are impaired — directly reducing the brain's capacity to produce the neurotransmitters that panic disorder treatment depends on.

A recent double-blind RCT found that high-dose B6 supplementation significantly reduced anxiety and reduced the frequency of auras and sensory hypersensitivity — effects attributed to its role in enhancing GABAergic tone. This is particularly relevant to panic disorder, where sensory hypersensitivity (interpreting normal physical sensations as dangerous) is a key cognitive component of the attack cycle.

At 25mg, this dose substantially exceeds deficiency thresholds and provides enough pyridoxine to fully support both serotonin and GABA synthesis pathways without exceeding safe supplementation limits.

Methylcobalamin is the biologically active form of B12 that the nervous system uses directly, without conversion. It is a critical substrate in the methylation cycle — the biochemical process that governs the synthesis and breakdown of serotonin, GABA, dopamine, and norepinephrine. Impaired methylation disrupts neurotransmitter regulation across all of these systems simultaneously.

B12 also maintains myelin — the protective sheath around nerve fibres that governs how quickly and reliably neurons signal. Panic disorder involves hyperreactivity in the pathways between the prefrontal cortex and the amygdala. Degraded myelin in these pathways may reduce the prefrontal cortex's ability to regulate amygdala activation — weakening the cortical "override" that prevents an anxiety signal from escalating into a full panic attack.

Low B12 is associated with increased anxiety, depressive symptoms, and cognitive symptoms that overlap with panic disorder presentations. Methylcobalamin is chosen specifically over cyanocobalamin because it is directly usable by the nervous system without a conversion step that some people — particularly those with MTHFR gene variants — cannot perform efficiently.